Share-based Payment Arrangement, Expense of PLIANT THERAPEUTICS, INC. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PLIANT THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • PLIANT THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $6,418,000, a 28% decline year-over-year.
  • PLIANT THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $30,129,000, a 21% decline year-over-year.
  • PLIANT THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $37,626,000, a 15% decline from 2023.
  • PLIANT THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $44,483,000, a 97% increase from 2022.
  • PLIANT THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $22,598,000, a 117% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PLIANT THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $30,129,000 $6,418,000 -$2,481,000 -28% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $32,610,000 $6,382,000 -$4,262,000 -40% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $36,872,000 $8,912,000 -$754,000 -7.8% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $37,626,000 $8,417,000 -$734,000 -8% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $38,360,000 $8,899,000 -$1,464,000 -14% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $39,824,000 $10,644,000 -$2,402,000 -18% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $42,226,000 $9,666,000 -$2,257,000 -19% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $44,483,000 $9,151,000 -$1,705,000 -16% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $46,188,000 $10,363,000 +$5,555,000 +116% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $40,633,000 $13,046,000 +$9,643,000 +283% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $30,990,000 $11,923,000 +$8,392,000 +238% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $22,598,000 $10,856,000 +$8,088,000 +292% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $14,510,000 $4,808,000 +$1,997,000 +71% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $12,513,000 $3,403,000 +$1,123,000 +49% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $11,390,000 $3,531,000 +$953,000 +37% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $10,437,000 $2,768,000 +$1,253,000 +83% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $9,184,000 $2,811,000 +$1,642,000 +140% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $7,542,000 $2,280,000 +$1,494,000 +190% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $6,048,000 $2,578,000 +$2,153,000 +507% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $3,895,000 $1,515,000 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $1,169,000 +$689,000 +144% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $786,000 +$280,000 +55% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $425,000 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q3 2019 $480,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $506,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2

PLIANT THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $37,626,000 -$6,857,000 -15% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $44,483,000 +$21,885,000 +97% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $22,598,000 +$12,161,000 +117% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $10,437,000 +$6,542,000 +168% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $3,895,000 +$2,066,000 +113% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $1,829,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.